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ABSTRACT 
Living donor liver transplantation (LDLT) is an alternative to traditional 
deceased donor liver transplantation (DDLT) that has grown out of the shortage of 
deceased donor livers available for transplantation. The two procedures have 
similar clinical outcomes, but costs have been shown to be higher in living donor 
liver transplantation (LDLT) than in deceased donor liver transplantation 
(DDLT). The aim of this study was to compare the medical resource utilization, 
costs, and complication rates between LDLT and DDLT. Data were collected on 
the first 24 LDLT recipients performed at the University of North Carolina at 
Chapel Hill School of Medicine and were compared to 24 DDLT recipients 
matched on age, etiology of liver disease, year of transplant, and model for end 
stage liver disease (MELD) score at the time of transplantation. The study time 
period was the first 30 days after transplantation. Compared to DDLT recipients, 
LDLT recipients had significantly longer lengths of stay, 23.2 vs. 15.9 days, 
p<0.001, as well as number of laboratory tests 2,403 vs. 1,509, p=0.001 and 
radiology tests, 29.9 vs. 14.7, p<0.001 . Costs for ICU care were higher in the 
LDLT recipients compared to DDLT recipients, $15,504 vs. $7,243, p=0.006. 
Total costs for LDLT recipients was higher at $61,488 vs. $34,973 for DDLT 
recipients, p=O.OOl. The increase in total costs in the LDLT group was largely 
driven by complications, with are-transplantation rate of 25%. Resource 
utilization and costs are higher in LDLT recipients than in DDLT recipients, and 
may be due the higher complication andre-transplantation rates seen in LDLT. 
These data may be useful to institutions planning to initiate a LDLT program. 
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INTRODUCTION 
Liver transplantation is the only curative treatment for patients with acute 
or chronic liver failure. Cadaveric or deceased donor liver transplantation 
(DDLT) entails removal of the donor liver from the cadaveric donor and 
implantation into the recipient after resection of the diseased liver. The first 
successful transplant was performed over 35 years ago 1. With increasing 
technical experience and improvements in immunosuppressive drugs, both the 
number of transplants and the survival rates has grown dramatically in the past 
several years 2·3. From 1989 to 1999 the number of liver transplants performed in 
the US increased from 2,201 to 4,700 4. During this same time period, average 1-
year survival rates increased from 81.5% to 86.2% and are currently greater than 
90% 5. Liver transplantation is now standard of care for patients with end-stage 
liver disease (ESLD). 
Unfortunately, the number of patients requiring liver transplantation will 
likely increase in the future. The peak of the hepatitis C epidemic has not yet 
been reached 6. There are approximately 25 million Americans infected- many 
of who do not know they are infected until they develop ESLD. As many as 20% 
of these patients infected with hepatitis C may eventually develop ESLD and 
require liver transplantation 7. 
With the dramatic increase in the number of procedures, the improvement 
in outcomes, and the increasing incidence of ESLD it is no surprise that the 
number of patients waiting for liver transplantation has also increased. The 
number of patients on the waiting list has increased more than 15-fold in the past 
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10 years. Unfortunately, the supply of organs has not kept up with the greater 
demand, increasing only 3-fold over the past 10 years 8. If listings were 
suspended at there current levels, it would take over 4 years to transplant all those 
patients currently on the waiting list 4. Because of this mismatch in waitlist length 
and supply of organs, waitlist times are increasing and more patients are dying 
waiting for a liver transplant 9 Currently, waiting list mortality is about 10% per 
year 8 
In response to this shortage, adult-to-adult living donor liver 
transplantation (LDLT) has evolved as an alternative for patients with ESLD and 
outcomes have been shown to be similar to DDLT 10-14. In LDLT, the recipient's 
diseased liver is resected, and the either a right or left liver lobe from a living 
donor is implanted. Because of the liver's tremendous regenerative ability, the 
liver fragment in both the donor and recipient quickly grows, and within a few 
weeks liver mass is normal in both donor and recipient. The use of LDLT has 
shortened the waiting time for some recipients and may indirectly increase the 
availability of deceased donor organs for those remaining on the DDLT waiting 
list 15 • 
As LDLT becomes more widely available, it is important to compare the 
differences in medical resource utilization and costs between the two procedures. 
The first study to do this was published in 2002 and was a cost effectiveness 
analysis based on a Markov model ofESLD patients treated conservatively (i.e. 
no transplant, medical management only), with DDLT alone, or with DDLT or 
LDLT. The model favored DDLT or LDLT over conservative treatment with an 
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additionall.3 quality adjusted life years in the group offered LDLT or DDLT 
compared to DDLT alone 16 This suggests that offering LDLT in addition to 
DDLT can improve survival at acceptable costs. Another study compared the 
comprehensive costs for 24 LDLT recipients for 90 days pre-operative and 1-year 
post-operative (including all donor evaluation and post-operative care) to 43 
DDLT recipients' care for the same time period. The total comprehensive cost of 
LDLT was 21% higher than DDLT, although this difference was not statistically 
significant. This was likely due to the case mix and patient factors not controlled 
for in the study making the sample size inadequate 17• Finally, one study 
published only in abstract form showed that LDLT donor evaluation, post-
operative care, and recipient post-operative care cost 2.8 times more than DDLT 
recipient post-operative care 18 • 
These prior studies comparing costs of LDLT to DDLT did not adjust for 
the severity of illness prior to transplant, which may have affected resource 
utilization in the immediate post-transplant period 19-22• These studies also did not 
adjust for time period and advances over time, which may impact practice 
patterns and costs. In order to accurately determine the differences in costs solely 
based on the type of transplant and not patient severity of illness, we matched 
patients on severity of illness using model for end-stage liver disease (MELD) 
score, age, etiology of liver disease, and year of transplantation. We compared 
the medical resource utilization and cost differences for only the first 30 days 
after transplantation because pre-transplant costs are difficult to accurately obtain 
because patients often seek care at multiple facilities. Most post-transplant costs 
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occur during the first 30 days. Also, most transplant contracts with the insurer are 
based upon the time from transplant to discharge, which typically occurs within 
30 days of transplantation. Additionally, we examined specific areas in which 
resource utilization was higher in LDLT compared to DDLT recipients, such as 
length of stay, laboratory testing, radiology testing, andre-operations. We also 
compared the frequencies of complications for the 30-day post-transplant time 
period between LDLT and DDLT recipients. 
MATERIALS AND METHODS 
The study group included the first 24 consecutive LDLT recipients 
performed at the University of North Carolina at Chapel Hill School of Medicine 
from November 1998 to October 2003. In order to most accurately capture costs 
related to the type of transplant, 24 DDLT recipients were matched to the LDLT 
recipients on factors that affect costs, including age, year of transplant, etiology of 
liver disease, and MELD score at the time of transplant (see Table 1). Data were 
collected by extensive review of both the electronic and paper medical record. 
The first 30 days after transplantation was used as the study time period. 
Complications were defined as any event prolonging hospital stay or requiring an 
intervention or administration of a medication not part of standard of care. 
Costs were obtained from the University of North Carolina Hospitals 
accounting office and reflect actual estimated costs, not charges, in US dollars to 
provide medical services. Costs are felt to be a more accurate and generalizable 
measure because charges have significant regional variation. Only 30 day post-
operative costs for LDLT and DDLT recipients are included in this analysis. 
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Costs of organ acquisition as well as donor evaluation and post-operative care of 
the donor were not included in this analysis. Professional fees were also excluded 
from this analysis. The cost analysis was performed from the perspective of the 
provider. 
Variables were summarized as means and standard deviations (SD) for 
variables with normal distribution, and medians and ranges for non-normally 
distributed variables. A variable was considered non-normally distributed if the 
median was substantially different from the mean. Means of continuous variables 
were compared using the 2-sample t-test. Medians of continuous variables were 
compared using the Wilcoxon rank sum test. Categorical variables were 
compared using Pearson's chi square test or Fisher's exact test when appropriate. 
Statistical analysis was performed using Stata Statistical Software: Release 8.0 
(Stata Corporation, College Station, TX). 
This study was approved by the institutional review board of the 
University of North Carolina at Chapel Hill School of Medicine. 
RESULTS 
Table 1 shows the demographics of the LDLT and DDLT groups. The 
groups were well matched for age, MELD score at the time of transplant, etiology 
of liver disease, and year of transplant. Median wait times tended to be longer in 
the DDLT group, although this did not reach statistical significance. The two 
groups were also similar prior to transplant when compared using the age-
weighted comorbidity index described by Charlson eta!., with the LDLT 
recipients having a mean comorbidity score of 4.5±1.3 and DDLT having a mean 
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score of 4.3±1.5, p=0.60 23 . Twenty-three of the 24 LDLT recipients received a 
right hepatic lobe, only one received a left lobe. Six LDLT recipients had a duct-
to-duct anastomosis while 21 of the DDLT recipients had this type of biliary 
anastomosis. One patient in the LDLT recipient group had hepatocellular 
carcinoma (HCC) at the time of transplantation, while no patient in the DDLT 
recipient group had HCC. For the cost and resource utilization comparisons 
described below, the results were similar when either means or medians were 
compared. 
Length of Stay 
Table 2 shows the differences in 30-day post-operative medical resource 
utilization between the two groups. LDLT recipients' length of stay was longer in 
the ICU compared to DDLT recipients, 13.0 vs. 5.7 days, respectively, p=0.004. 
Total length of stay was longer in the LDLT group at 23.2 days vs. 15.9 days in 
the DDLT group, respectively, p<O.OOl. The longer length of stay in the LDLT 
recipients was driven by ICU stay, because length of stay on the floor was 10.2 
days in both groups. 
Medical Resource Utilization 
The LDLT recipients also had significantly more days spent on the 
ventilator, 10.0±11.1 days compared to 2.6±2.4 days in the DDLT recipients, 
p=0.002. The LDLT recipients had significantly greater numbers of laboratory 
tests (p=O.OOl), radiology tests (p<O.OOl), andre-operations (p=0.002) (see Table 
2). Blood products include the total number of blood products (packed red blood 
cells, fresh frozen plasma, platelets, and cryoprecipitate) given during the 30-day 
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post-operative period. Re-operations include any time the patient was taken back 
to the operating room during the 30-day post-operative period, including re-
transplantation. The mean number of medication doses (both inpatient and 
outpatient dispensed at one of our hospital's pharmacies) was higher in the LDLT 
recipient group, although this did not reach statistical significance even after 
adjusting for the unequal variance. 
Cost 
Cost data are shown in Table 3. Total and ICU room charges were 
significantly higher in the LDLT recipient group, reflective of this group's longer 
hospitalization. The LDLT recipient group incurred significantly higher 
medication, radiology, and operating room costs; while laboratory, blood bank, 
and other costs (which includes non-OR procedures, dialysis, and respiratory 
therapy costs) tended to be higher in the LDLT group, although not statistically 
significant. While the number of medication doses was higher, but not 
statistically significant, in the LDLT recipients, the costs for providing these 
medications were nearly twice as high in the LDLT recipients, p=O.Ol. This may 
be due to the use of medications with higher costs. Costs related to operating 
room time were nearly 9 times higher in the LDLT recipients. Operating room 
costs accounted for 8% of the total costs in the LDLT recipients, while only 2% of 
the total costs for the DDLT recipients. This difference is likely due to the higher 
rate of graft failure andre-transplantation in the LDLT recipients. Total costs for 
the 30-day post-operative period are nearly twice as high in the LDLT recipient 
group, p=O.OOl. 
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Complications 
This cost differential between the two groups was largely due to the higher 
complication rate seen in the LDLT recipient group as shown in Table 4. There 
were no deaths in either group seen in this 30-day post-operative period. 
Biliary Complications 
There were more biliary leaks in the LDLT recipient group than in the 
DDLT recipient group, although this was not statistically different. Three patients 
in the LDLT recipient group had bile leaks from the cut surface of the liver, two 
of which resolved with percutaneous drainage and one required surgical 
intervention. Two patients had anastomotic leaks, one of which resolved with 
percutaneous biliary drainage and the other required surgical revision of the 
anastamosis. The one biliary leak seen in the DDLT recipient group was 
anastomotic and was managed successfully with endoscopic retrograde 
cholangiopancreatography (ERCP) and biliary stenting. No biliary stenoses were 
seen in this in this 30-day post-operative period. 
Vascular Complications 
Five patients in the LDLT recipient group suffered hepatic artery 
thrombosis (HAT), while no patients in the DDLT recipients had HAT. 
Unfortunately, all 5 occurrences of HAT led to loss of the graft andre-
transplantation. Venous stenoses of either the vena cava or hepatic veins were 
seen in 3 patients in the LDLT recipient group and 2 patients in the DDLT 
recipient group- all of which were successfully managed with endovascular 
stenting. The number of bleeding occurrences tended to be higher in the LDLT 
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recipient group. Three patients required evacuation of hematoma from the cut 
liver surface, while 2 had vena cava bleeding and one had a hepatic artery leak. 
The 3 patients in the DDLT recipient group with bleeding complications all had 
hematoma evacuation. 
Infections 
Rates of infection were also significantly higher in the LDLT recipient 
group, p=0.05. There were three cases of uncomplicated urinary tract infections, 
which resolved with antibiotics. One minor wound infection also resolved 
uneventfully with antibiotics. Another patient developed nosocomial pneumonia 
and recovered with antibiotics and supportive care. Five patients developed post-
operative peritonitis, 2 caused by gram-positive cocci and 3 by gram-negative 
rods. All were successfully managed with antibiotics. In the DDLT recipient 
group, one patient developed a minor wound infection and another a transient 
gram-positive cocci bacteremia, both of which were successfully managed with 
antibiotics. One patient was diagnosed with cholangitis on liver biopsy and 
successfully treated with antibiotics. 
Rejection 
Rejection was the only complication that did not occur at a higher rate for 
the LDLT recipients. There was no significant difference in rejection between the 
two groups, p=0.70. Two patients in the LDLT recipient group were diagnosed 
with acute cellular rejection based on rejection activity indexes (RAI) of 5 and 3 
24
• Four patients in the DDLT recipient group were successfully treated for 
rejection with RAI's of3, 5, 5, and 6. 
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DISCUSSION 
While LDLT is still a relatively new option for patients with ESLD, 
several studies have now shown that graft and patient survival rates are acceptable 
and comparable to DDLT 10-14. Although outcomes are similar with LDLT 
compared to DDLT, much less is known about resource utilization after LDLT 
compared to DDLT. Understanding major areas of resource utilization with 
LDLT and the differences compared to DDLT may help in improving delivery of 
care and focus on areas that need improvement. 
In this study, the first 24 LDLT recipients performed at our institution 
were matched to 24 DDLT recipients, including severity of illness based on 
MELD score at the time of transplant. The two groups were well matched which 
should eliminate differences in patient characteristics rather than type of 
transplant as an explanation for greater resource utilization in the LDLT. After 
adjusting for severity of illness and time period, 30-day post-transplantation costs 
and resource utilization were higher in the LDLT recipients compared to the 
DDLT recipients. Most of the increase in costs in the LDLT recipients was due to 
increased ICU stay and higher complication rates compared to the DDLT 
recipient group. 
Complications were higher in the LDLT group compared to the DDLT 
group, but others have reported that outcomes do not approach those ofDDLT 
until after the first 20 LDLT's 17•25 • The rate of 25% for hepatic artery thrombosis 
is higher than anticipated based upon prior reports, but our 1-year graft survival of 
75% is similar. The first 4 graft losses in the LDLT recipients occurred within the 
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first 15 cases done within the first 2 years of our LDLT program. Only 2 graft 
losses have been seen within the past 4 years at our institution, suggesting that 
this early high complication rate and graft loss may be part of the LDLT learning 
curve. Since this study represents our early experience with LDLT, our analysis 
may be biased against LDLT since we have been performing DDLT for a much 
longer period of time. However, despite this limitation, these data are useful, 
especially for centers planning an LDLT program. 
The increase in total costs in the LDLT group was largely attributed to L 
surveillance or treatment of vascular complications, either hepatic artery 
thrombosis or venous outflow obstruction. All of the LDLT recipients with 
hepatic artery thrombosis were re-transplanted, which accounted for most of the 
$4,400 difference in operating rooms costs between the two groups. The LDLT 
group had more radiological imaging, including Doppler ultrasound and 
abdominal CT scan, which is at least part! y due to our programs heightened 
awareness of the risk of vascular complication in this group. After 15 LDLT' s the 
risk of vascular complications decreased, but utilization of radiology did not 
follow the same pattern. 
This study has several limitations. The study time period included only 
the first 30 days after transplantation. The 30 day post-operative time period was 
chosen for this study because most complications and intensive medical care and 
hence costs in liver transplantation usually occurs within the early post-operative 
time period 26. However, pre-transplant costs related to patient care and transplant 
evaluation, donor evaluation, organ procurement, and post-transplant costs related 
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to care of both the recipients and donors after 30 days is not captured. On the pre-
transplant side, LDLT may actually be more cost-effective by shortening waiting 
times and reducing the number of complications while candidates wait for 
transplantation 27 . As liver disease progresses, costly complications related 
primarily to portal hypertension also increase in both frequency and severity. The 
cost of transjugular intrahepatic portosystemic shunting may be as high as 
$15,000 28. As patients become more debilitated, they often cannot work leading 
to a significant economic impact- especially since most patients are between the 
ages of 45 and 65 27 Because these potential pre-transplant cost savings were not 
captured in this analysis the results are biased against LDLT. In the peri-
transplant time period, LDLT donor evaluation and post-operative care may be 
only partially offset by DDLT organ acquisition costs. The inclusion of these data 
would have likely increased the differences already seen in resource utilization 
and costs between the LDLT and DDLT recipient groups. This study also likely 
underestimates costs and resource utilization in both groups. Professional fees 
were not included in this analysis, but would likely have increased the costs 
similarly in both groups. This is a small study, with only 24 patients in each 
group. However, even with small numbers, the study found statistically 
significant differences between the LDLT and DDLT recipient groups with 
respect to medical resource utilization and costs. 
This novel method of analysis- controlling for patient characteristics 
including comorbidities by matching on clinical factors which measure severity of 
illness, then comparing cost and resource utilization over a defined time period 
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may be a useful way to compare new medical innovations to standard of care. It 
combines a health services approach and epidemiological methods, both of which 
are standard in public health. As seen in this study, this methodology is 
particularly useful with limited data, e.g. a small sample size over a short time 
period. This method may be a valuable planning and evaluation tool for 
institutions considering initiating a new medical treatment program and 
comparing its costs and resource utilization to standard of care. 
In the future, it may be interesting to repeat this cost analysis on the next 
24 LDLT's performed at our institution, again controlling for patient severity of 
illness. Improvements in the technical aspects of the procedure and/or 
management of post-operative complications may well lead to decreased costs 
over time. Also, an analysis comparing pre-transplant medical costs and resource 
utilization from the time of listing to the time of transplantation between LDLT 
and DDLT recipients could elucidate potential cost savings in LDLT related to 
shorter wait times. Little is know about the long-term complications related to 
LDLT. Future studies may expand the post-operative period of analysis out to 
many years. 
In summary, this study attempts to address post-operative costs while 
controlling for severity of illness prior to transplantation by matching on MELD 
score. This insures that the patients in the DDLT and LDLT groups have equal 
severity of illness just prior to transplantation. Therefore, the significantly higher 
medical resource utilization and costs, which are nearly twice as high during the 
30-day post-operative period increased costs seen with LDLT, are likely related to 
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post-operative complications. Higher complication and graft failure rates in the 
LDLT recipient group may partly account for these increased costs. The higher 
costs of LDLT should be taken into consideration when allocating resources for 
liver transplantation, especially in centers initiating a LDLT program. Continued 
experience and technical improvements in LDLT may lead to lower resource 
utilization and costs in the future. 
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TABLES 
Table 1. Patient Characteristics. 
LDLT Recipient DDLT Recipient 
n=24 n=24 
Mean (SD) or n(%) Mean (SD) or n(%) Pvalue 
Age* 50 (11) 50 (10) 0.86 
Male/Female 11 (46% )/13 (54%) 12 (50% )112 (50%) 0.77 
Race 0.57 
White 22 (92%) 22 (92%) 
Black 0 1 (4%) 
Hispanic 1 (4%) 1 (4%) 
Asian 1 (4%) 0 
Etiology of Liver Disease* 0.80 
HCV 7 (30%) 6 (25%) 
Alcohol 2 (8%) 3 (13%) 
HCV I Alcohol 1 (4%) 1 (4%) 
Cryptogenic/NASH 2 (8%) 3 (13%) 
Autoimmune 1 (4%) 2 (8%) 
PBC 4 (17%) 0 
PSC 2 (8%) 4(17%) 
Other 5 (25%) 5 (25%) 
MELD at Transplant* 15 (7) 17 (6) 0.07 
Charlson Comorbidity Index 4.5 (1.3) 4.3 (1.5) 0.60 
Year of Transplant* 0.83 
1998-1999 8 (33%) 7 (29%) 
2000-2001 12 (50%) 12 (50%) 
2002-2003 4 (17%) 5 (21 %) 
Median Wait in days (range) 313 (21-1119) 483 (4-2542) 0.15 
*Indicates criteria on which the two groups were matched. 
Abbreviations: LDLT, living donor liver transplantation; DDLT, deceased donor 
liver transplantation; SD, standard deviation; HCV, hepatitis C; NASH, non-
alcohol steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing 
cholangitis. 
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Table 2. Medical Resource Utilization. 
LDLT Recipient DDLT Recipient 
n=24 n=24 
Mean (SD) Mean (SD) Pvalue 
Length of Stay (days) 
ICU 13.0 (11.1) 5.7 (4.4) 0.004 
Floor 10.3 (7.9) 10.3 (5.7) 1.00 
Total 23.2 (7.2) 15.9 (6.2) <0.001 
Days ventilated 10.0 (11.1) 2.6 (2.4) 0.002 
Laboratory tests 2,403 (I ,205) 1,509 (451) 0.001 
Medication doses 1,533 (1,331) 1,015 (753) 0.13 
Radiology tests 29.9 (17.1) 14.7 (5.9) <0.001 
Re-operations 1.3 (1.4) 0.3 (0.5) 0.002 
Blood products (total# 50.8 (45.4) 33.9 (21.1) 0.11 
units) 
Abbreviations: LDLT, living donor liver transplantation; DDLT, deceased donor 
liver transplantation; SD, standard deviation; ICU, intensive care unit. 
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Table 3. Medical Costs 
LDLT Recipient DDLT Recipient 
n=24 n=24 
Mean (SD)* Mean (SD)* Pvalue 
Room costs 
ICU $15,504 (12,769) $7,243 (5,548) 0.006 
Floor $7,612 (5,766) $7,703 (4,107) 0.95 
Total $23,117 (9 ,297) $14,947 (5,905) <0.001 
Laboratory $10,022 (7,210) $6,965 (2,923) 0.06 
Medications $9,922 (6,849) $5,408 ( 4,993) 0.01 
Radiology $3,610 (1,764) $1,644 (872) <0.001 
Operating Room $4,968 (6,248) $561 (1,223) 0.001 
Blood Products $5,490 (5,997) $3,735 (2,809) 0.20 
Other** $4,319 (1,690) $1,711 (708) 0.16 
Total $61,488 (33,208) $34,973 (15,680) 0.001 
*Means are in US Dollars. 
**Other costs include non-operating room procedures, dialysis, and respiratory 
therapy. 
Abbreviations: LDLT, living donor liver transplantation; DDLT, deceased donor 
liver transplantation; SD, standard deviation; ICU, intensive care unit. 
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Table 4. Complications. 
LDLT Recipient DDLT Recipient 
n=24 n=24 
total # complications total # complications Pvalue 
Biliary 
Leak 5 1 0.2 
Stenosis 0 0 
Vascular 
HAT 5 0 0.05 
Stenosis 3 2 1 
Bleeding 6 3 0.5 
Infection 10 3 0.05 
Rejection 2 4 0.7 
Graft Failures 6 0 0.02 
Death 0 0 
Abbreviations: LDLT, living donor liver transplantation: DDLT, deceased donor 
liver transplantation; HAT, hepatic artery thrombosis. 
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